| Window | Theses | Resolved | Wins | Win rate | Avg return | Median return |
|---|---|---|---|---|---|---|
| 1d | — | — | — | — | — | — |
| 3d | — | — | — | — | — | — |
| 1w | — | — | — | — | — | — |
| 1m | — | — | — | — | — | — |
| 3m | — | — | — | — | — | — |
| 6m | — | — | — | — | — | — |
| 1y | — | — | — | — | — | — |
Past performance does not predict future results. Informational only, not investment advice.
Healthcare ETF recommended as a diversified alternative to picking individual stocks in the undervalued healthcare sector, benefiting from demographic tailwinds and AI-driven innovation.
Healthcare ETF recommended as a diversified alternative to picking individual stocks in the undervalued healthcare sector, benefiting from demographic tailwinds and AI-driven innovation.
Healthcare ETF recommended as a diversified alternative to picking individual stocks in the undervalued healthcare sector, benefiting from demographic tailwinds and AI-driven innovation.
Healthcare ETF recommended as a diversified alternative to picking individual stocks in the undervalued healthcare sector, benefiting from demographic tailwinds and AI-driven innovation.
Dexcom is mentioned as a comparison point for MMED valuation; author suggests MMED's revenue generation relative to DXCM's 31B market cap indicates potential mispricing in the biotech/medical device space.
Abbott Laboratories is positioned as a value play in the healthcare sector, with structural growth from aging demographics and potential AI applications in life-saving products.
Recently-IPO'd biotech with 5B market cap and 27 PE offers significant upside potential, trading at a discount relative to peers like DXCM; author sees path to 10-15B valuation within a couple years driven by revenue growth.
Regeneron represents a value opportunity in healthcare, benefiting from sector tailwinds including aging demographics and AI integration into life-saving therapeutics.
Medical device manufacturer offers good value in the healthcare sector, which is poised for growth driven by demographic trends (aging population) and AI-enhanced product opportunities.
End of results.